Skip to content

Midazolam Hydrochloride

DRUG18 trials

Sponsors

Heidelberg University Hospital AöR, Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI), Boehringer Ingelheim, Daiichi Sankyo

Conditions

Adult Solid NeoplasmAdvanced Solid TumorAlcohol Use DisorderAmnesia-Memory LossAnesthesiaAnesthesia ComplicationAtopic DermatitisBipolar Depression

Phase 1

Effect of Affective Content on Drug Induced Amnesia of Episodic Memory
CompletedNCT00142493
Memorial Sloan Kettering Cancer CenterAmnesia-Memory Loss, Memory Losses
Start: 2004-09-30End: 2008-08-31Updated: 2015-12-24
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
CompletedNCT01218620
National Cancer Institute (NCI)Adult Solid Neoplasm
Start: 2010-09-30End: 2014-12-31Updated: 2014-12-23
Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers
CompletedNCT02256813
Boehringer IngelheimHealthy
Start: 2005-09-30Updated: 2014-10-06
A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS
CompletedNCT02473627
Daiichi SankyoHealthy
Start: 2015-05-31End: 2015-07-31Updated: 2015-11-05
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
CompletedNCT03330990
Hoffmann-La RocheAdvanced Solid Tumor
Start: 2017-11-14End: 2018-07-11Updated: 2018-08-21
Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
CompletedNCT03457597
Corcept TherapeuticsHealthy
Start: 2018-03-06End: 2018-04-28Updated: 2018-05-17
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
CompletedNCT03556592
LEO PharmaAtopic Dermatitis
Start: 2018-08-13End: 2020-06-20Updated: 2025-02-24
Ketamine for Combined Depression and Alcohol Use Disorder
Not yet recruitingNCT06090422
University Hospital of North NorwayAlcohol Use Disorder, Depression
Start: 2025-01-01End: 2027-07-01Target: 34Updated: 2024-09-19
Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery
CompletedNCT06867068
Albert Einstein College of MedicineAnesthesia, Tooth Extraction
Start: 2016-10-04End: 2024-06-10Updated: 2026-03-27

Phase 2

Investigation of Antidepressant Efficacy of Oral Ketamine Treatment
NCT02992496
Medical University of ViennaMajor Depressive Episode
Start: 2017-04-24End: 2020-12-31Target: 60Updated: 2019-09-03
Ketamine for Treatment-Resistant Bipolar Disorder
CompletedNCT05004896
Joshua RosenblatBipolar Depression, Bipolar Disorder, Bipolar I Disorder +1
Start: 2022-07-04End: 2025-11-14Updated: 2026-03-05
Long-term neuropsychologic outcome of pre-emptive mTOR inhibitor treatment in children with tuberous sclerosis complex (TSC) under 4 months of age (PROTECT)
RecruitingCTIS2022-502332-39-00
Heidelberg University Hospital AöRTuberous sclerosis complex (TSC)
Start: 2023-11-15Target: 64Updated: 2025-08-25
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial
RecruitingNCT06480500
University Health Network, TorontoMajor Depressive Disorder, Suicide, Treatment Resistant Depression
Start: 2024-01-02End: 2026-06-30Target: 110Updated: 2025-12-05
Ketamine for Methamphetamine Use Disorder
RecruitingNCT06496750
University of Texas Southwestern Medical CenterMethamphetamine Abuse, Substance Use, Substance Use Disorders
Start: 2024-09-11End: 2026-10-15Target: 120Updated: 2026-04-01
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)
Not yet recruitingNCT07569198
Joshua RosenblatBipolar Disorder (BD), Bipolar Disorder I or II, Borderline Personality Disorder (BPD) +4
Start: 2026-06-01End: 2029-08-01Target: 120Updated: 2026-05-06

Phase 3

Phase 4

Related Papers